Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro

Breast Cancer Research and Treatment

Volumn 51, Issue 2, 1998, Pages 139-148

  Bontenbal, Marijke ^a   Sieuwerts, Anieta M ^a   Peters, Harry A ^a   Van Putten, Wim L J ^a   Foekens, John A ^a   Klijn, Jan G M ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Breast cancer; Doxorubicin uptake; Estrogenic recruitment

Indexed keywords

DNA; DOXORUBICIN; ESTRADIOL; INTERCALATING AGENT;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; ESTRADIOL; FEMALE; FLOW CYTOMETRY; HORMONES; HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASMS, HORMONE-DEPENDENT; TUMOR CELLS, CULTURED;

EID: 0031773712     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006026015448     Document Type: Article

References (34)

1. Launchbury AP, Habboubi N: Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev 19: 197-228, 1993
2. The French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6: 679-688, 1988
3. Italian Multicenter Breast Study with Epirubicin: Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicenter trial. J Clin Oncol 6: 976-982, 1988
4. Levine M, Bramwell V, Pritchard K, Shepherd L: CEF versus CMF in premenopausal women - Recent update. Sixth International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen, Switzerland, February 25-28, 1998, abstract S35
5. Liu LF, Rowe TC, Yang L, Tewey KM, Chen GL: Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-15370, 1983
6. Sinha BK, Katki AG, Bastist G, Cowan KH, Myers CE: Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast cells: implication for the mechanisms of action. Biochemistry 26: 3776-3781, 1987
7. Chabner BA, Myers CE: Antitumor antibiotics. In: De Vita V, Hellman S, Rosenberg S (eds) Cancer, Principles and Practice of Oncology, 4th edition. JB Lippincott, Philadelphia, 1993, pp 376-380
8. Beck WT: The cell biology of multiple drug resistance. Biochem Pharmacol 36: 2879-2887, 1987
9. Endicott JA, Ling V: The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989
10. Lehner M: Reversal of multidrug resistance in breast cancer: many more open questions than answers. Ann Oncol 4: 11-13, 1993
11. Bontenbal M, Sieuwerts AM, Klijn JGM, Peters HA, Krijnen HLJM, Sonneveld P, Foekens JA: Effect of hormonal manipulation and doxorubicin administration on cell kinetics of human breast cancer cells. Br J Cancer 60: 688-692, 1989
12. Weichselbaum RR, Hellman S, Piro AJ, Nove JJ, Little JB: Proliferation kinetics of a human breast cancer line in vitro following treatment with 17β-estradiol and 1-β-D-arabino-furanosylcytosine. Cancer Res 38: 2339-2342, 1978
13. Clarke R, van der Berg HW, Kennedy DJ, Murphy RF: Estrogen receptor status and the response of human breast cancer cell lines to a combination of methotrexate and 17β-estradiol. Br J Cancer 51: 365-369, 1985
14. Hug V, Johnston D, Finders M, Hortobagyi G: Use of growth stimulatory hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 46: 147-152, 1986
15. Bontenbal M, Sieuwerts AM, Peters HA, Sonneveld P, Foekens JA, Klijn JGM: Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells. J Steroid Biochem Molec Biol 37: 1097-1101, 1990
16. Remvikos Y, Jouve M, Beuzeboc P, Viehl P, Magdelenat H, Pouillart P: Cell cycle modifications of breast cancers during neo-adjuvant chemotherapy: a flow cytometry study on fine needle aspirates. Eur J Cancer 13: 1843-1848, 1993
17. Daidone MG, Silvestrini R, Valentinis B, Ferrari L, Bartoli C: Changes in cell kinetics induced by primary chemotherapy in breast cancer. Int J Cancer 47: 380-383, 1991
18. Israel M, Pegg WJ, Wilkinson PM, Garnick M: Liquid chromatographic analysis of adriamycin and metabolites in biological fluids. J Liquid Chromatography 6: 795-809, 1985
19. Kokenberg H, Sonneveld P, Delwel R, Sizoo W, Hagenbeek A, Löwenberg B: In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 2: 511-517, 1988
20. Citro G, Cucco C, Verdina A, Zupi G: Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64: 534-536, 1991
21. Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Roe DJ, Trent JM: Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer 63: 923-929, 1991
22. Schuurhuis GJ, Broxterman HJ, Cervantes A, van Heijningen ThHM, de Lange JHM, Baak JPA, Pinedo HM, Lankelma J: Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst 81: 1887-1892, 1989
23. Tokita N, Raju MR: Cell cycle dependent adriamycin uptake in Chinese hamster cells. Eur J Cancer Clin Oncol 21: 243-246, 1985
24. Minderman H, Linssen P, Wessels J, Haanen C: Cell cycle related uptake, retention and toxicity of idarubicin, daunorubicin and doxorubicin. Anticancer Res 13:1161-1166, 1993
25. cdc2/cyclin B activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49: 832-841, 1996
26. Epstein RJ, Smith PJ, Watson JV, Bleehan NM: Characterisation of VP-16-induced DNA cleavage in oestrogen stimulated human breast cancer cells. Br J Cancer 57: 445-450, 1988
27. Epstein RJ, Smith PJ: Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with toposiomerase II-interactive antitumor drugs. Cancer Res 48: 297-303, 1988
28. Epstein RJ, Smith PJ, Watson JV, Waters C, Bleehan NM: Oestrogen potentiates topoisomerasc-II-mediated cytotoxicity in an activated subpopulation of human breast cancer cells: Implications lor cytotoxic drug resistance in solid tumours. Int J Cancer 44: 501-505, 1989
29. Shaikh NA, Owen AM, Ghilchik MW, Braunsberg H: Actions of medroxyprogesterone acetate on the efficacy of cytotoxic drugs: Studies with human breast cancer cells in culture. Int J Cancer 43: 458-463, 1989
30. Shaikh NA, Owen AM, Ghilchik MW, Braunsberg H: Adriamycin action on human breast cancer cells: Enhancement by medroxyprogesterone acetate. Int J Cancer 43: 733-736, 1989
31. Reed MJ, Ross MS, Ghilchik MW: The effect of oestrogens and medroxyprogesterone acetate on the uptake of cytotoxic drugs by MCF-7 breast cancer cells. Anticancer Res 12: 533-536, 1992
32. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7: 710-717, 1989
33. Jancis EM, Carbone R, Loechner KJ, Dannies PS: Estradiol induction of rhodamine 123 efflux and the multidrug resistance pump in rat pituitary tumor cells. Mol Pharmacol 43: 51-56, 1992
34. Bontenbal M, Sonneveld P, Foekens JA, Klijn JGM: Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). Fur J Cancer Clin Oncol 24: 1409-1414, 1988